These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7658646)

  • 1. Immunoblot analysis using recombinant protein of the 180 kD bullous pemphigoid antigen NC16a domain as an aid to the diagnosis of atypical subepidermal autoimmune bullous skin diseases.
    Hashimoto T; Matsumura K; Kawahara Y; Ohata Y; Nishikawa T
    Keio J Med; 1995 Jun; 44(2):62-6. PubMed ID: 7658646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of antigens recognized by autoantibodies in herpes gestationis. Usefulness of immunoblotting using a fusion protein representing an extracellular domain of the 180 kD bullous pemphigoid antigen.
    Murakami H; Amagai M; Higashiyama M; Hashimoto K; Chorzelski TP; Bhogal BS; Jenkins RE; Black MM; Zillikens D; Nishikawa T; Hashimoto T
    J Dermatol Sci; 1996 Nov; 13(2):112-7. PubMed ID: 8953410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801.
    Zillikens D; Herzele K; Georgi M; Schmidt E; Chimanovitch I; Schumann H; Mascaro JM; Diaz LA; Bruckner-Tuderman L; Bröcker EB; Giudice GJ
    J Invest Dermatol; 1999 Dec; 113(6):947-53. PubMed ID: 10594735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullous pemphigoid sera that contain antibodies to BPAg2 also contain antibodies to LABD97 that recognize epitopes distal to the NC16A domain.
    Egan CA; Taylor TB; Meyer LJ; Petersen MJ; Zone JJ
    J Invest Dermatol; 1999 Feb; 112(2):148-52. PubMed ID: 9989788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 230-kD basic protein is the major bullous pemphigoid antigen.
    Mueller S; Klaus-Kovtun V; Stanley JR
    J Invest Dermatol; 1989 Jan; 92(1):33-8. PubMed ID: 2462597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoblot analysis of autoantigens in localized pemphigoid and pemphigoid nodularis.
    Kawahara Y; Matsumura K; Hashimoto T; Nishikawa T
    Acta Derm Venereol; 1997 May; 77(3):187-90. PubMed ID: 9188867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The majority of bullous pemphigoid and herpes gestationis serum samples react with the NC16a domain of the 180-kDa bullous pemphigoid antigen.
    Matsumura K; Amagai M; Nishikawa T; Hashimoto T
    Arch Dermatol Res; 1996 Aug; 288(9):507-9. PubMed ID: 8874743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule.
    Hamada T; Nagata Y; Tomita M; Salmhofer W; Hashimoto T
    Exp Dermatol; 2001 Aug; 10(4):256-63. PubMed ID: 11493314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.
    Chimanovitch I; Hamm H; Georgi M; Kroiss M; Stolz W; Apitz C; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Apr; 136(4):527-32. PubMed ID: 10768652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. False-negative results in immunoblot assay of serum IgA antibodies reactive with the 180-kDa bullous pemphigoid antigen: the importance of primary incubation temperature.
    Pas HH; Kloosterhuis GJ; de Jong MC; Jonkman MF
    Br J Dermatol; 2001 Dec; 145(6):986-9. PubMed ID: 11899154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins.
    Nakatani C; Muramatsu T; Shirai T
    Br J Dermatol; 1998 Sep; 139(3):365-70. PubMed ID: 9767278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
    Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
    Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular heterogeneity of the bullous pemphigoid antigen as detected by immunoblotting].
    Izumi H; Hosokawa H
    Nihon Hifuka Gakkai Zasshi; 1989 Jul; 99(8):871-5. PubMed ID: 2685419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a 160-kD molecule as a component of the basement membrane zone and as a minor bullous pemphigoid antigen.
    Zhu XJ; Niimi Y; Bystryn JC
    J Invest Dermatol; 1990 Jun; 94(6):817-21. PubMed ID: 1693941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting.
    Labib RS; Anhalt GJ; Patel HP; Mutasim DF; Diaz LA
    J Immunol; 1986 Feb; 136(4):1231-5. PubMed ID: 2418109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of skin basement membrane zone antibodies in the urine of patients with acquired subepidermal immunobullous diseases.
    Allen J; Shears E; Powell J; Wojnarowska F
    Br J Dermatol; 2001 Mar; 144(3):540-5. PubMed ID: 11260011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary peptides against the major epitope in the NC16A domain of BP180 show no specificity as vaccines to bullous pemphigoid.
    Nie Z; Garrod DR; Chan LS; Hashimoto T
    J Dermatol Sci; 1999 Nov; 21(3):157-64. PubMed ID: 10527376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera.
    Joly P; Courville P; Lok C; Bernard P; Saiag P; Dreno B; Delaporte E; Bedane C; Picard C; Sassolas B; Plantin P; D'Incan M; Chosidow O; Pauwels C; Lambert D; Loche F; Prost C; Tancrede-Bohin E; Guillaume JC; Roujeau JC; Gilbert D; Tron F; Vaillant L;
    Dermatology; 2004; 208(1):16-20. PubMed ID: 14730231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
    Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
    J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the relationship of the 230-kD and 180-kD bullous pemphigoid antigens.
    Robledo MA; Kim SC; Korman NJ; Stanley JR; Labib RS; Futamura S; Anhalt GJ
    J Invest Dermatol; 1990 Jun; 94(6):793-7. PubMed ID: 2192002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.